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High attrition rates of novel anti-cancer drugs highlight the need for improved models to 
predict toxicity. Although polo-like kinase 1 (Plk1) inhibitors are attractive candidates for drug 
development, the role of Plk1 in primary cells remains widely unexplored. Therefore, we evaluated 
the utility of an RnA interference-based model to assess responses to an inducible knockdown 
(iKD) of Plk1 in adult mice. Here we show that Plk1 silencing can be achieved in several organs,   
although adverse events are rare. We compared responses in Plk1-iKD mice with those in 
primary cells kept under controlled culture conditions. In contrast to the addiction of many 
cancer cell lines to the non-oncogene Plk1, the primary cells’ proliferation, spindle assembly and 
apoptosis exhibit only a low dependency on Plk1. Responses to Plk1-depletion, both in cultured 
primary cells and in our iKD-mouse model, correspond well and thus provide the basis for using 
validated iKD mice in predicting responses to therapeutic interventions. 
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A
lthough mice and humans are different, genetically engi-
neered mouse models (GEMMs) in cancer research faith-
fully reflect many of the fundamental traits of human can-
cer, which suggests that they are valuable tools for understanding 
the biology of tumour development and growth1. In conventional 
knockouts, the loss of a vital gene often leads to embryonic lethality 
or severe developmental abnormalities, which obscure the study 
of potential functions in the adult organism. To circumvent these 
obstacles, conditional genetic engineering technologies have been 
developed to control gene expression spatially and temporally. One 
current strategy is controlled expression of site-specific recombi-
nases to delete the specific gene of interest2. Alternatively, loss-of-
function studies use sequence-specific RNA interference (RNAi)-
based approaches to silence the expression of target genes3; this 
method often recapitulates the clinical effects of anti-cancer drugs 
better than transgenic models with null phenotypes because under 
clinical conditions, specific cancer targets are only partially inhib-
ited  and  are  often  time-limited  depending  on  the  applied  drug 
scheduling2,4.
Anti-mitotic drugs that inhibit microtubule dynamics have been 
successful in the treatment of cancer5,6. Still, their effectiveness is lim-
ited by two critical aspects: resistance and toxicity (myelosuppres-
sion and neuropathies). In efforts to avoid adverse side effects, small 
molecule inhibitors were developed to target the critical regulators 
of mitosis, such as polo-like kinase 1 (Plk1), that are overexpressed 
in a wide range of tumour types7–11. In vertebrate cells, Plk1 has 
been implicated in multiple steps of mitotic progression including 
the activation of Cdk1/cyclin B1 (ref. 12), centrosome maturation,   
release of cohesion from chromosomes, activation of the anaphase-
promoting  complex/cyclosome,  formation  of  bipolar  spindles   
and the regulation of the spindle assembly checkpoint (SAC)8,13–15. 
Inhibitors targeting Plk1 have recently entered the clinic16.
Because the role of Plk1 in primary normal cells remains widely 
unexplored and homozygous Plk1 null-mice are embryonic lethal17, 
in this study we generated an inducible RNAi-based GEMM as a 
tool to determine the function of mammalian Plk1 in adult mice 
and to monitor putative adverse events. We explored the effects of 
Plk1 gene dosage on the mitotic activity and induction of apoptosis 
in primary cells in vivo and in vitro. Our results suggest that trans-
genic inducible RNAi technology is helpful for modelling the func-
tion of pharmacologically relevant targets in adult mice.
Results
Examining Plk1 knockdown in embryonic stem cells. The first 
aim of this study was to model the function of Plk1 in adult mice 
using an inducible RNAi technique. We tested 18 small hairpin 
RNA (shRNA) constructs targeting murine Plk1 at different sites 
in  NIH3T3  and  RENCA  cells.  Plk1  silencing  was  induced  by 
various shRNAs, which suggests that the effect was not due to the   
off-target effects from a single-RNAi site. We selected the shRNA-
Plk1/1473 because it knocked down Plk1 mRNA by more than 70% 
(Supplementary Table S1). To prevent the chromosomal positional 
effects associated with the random nature of transgene integration, we 
inserted a cassette for shRNA expression into the well-characterized 
euchromatic locus Rosa26. The shRNA sequence Plk1/1473 was 
placed under the control of our previously generated inducible H1 
promoter along with a genetic element for the constitutive expression 
of the codon-optimized tetracycline repressor protein (itetR)18–21 
(Supplementary  Fig.  S1a).  The  standard  transfection  procedures 
using  this  exchange  vector  were  followed  by  the  recombinase-
mediated integration, which resulted in more than 90% positive 
embryonic stem (ES) cell clones (Supplementary Fig. S1b–d). The 
doxycycline (Dox)-dependent expression of shPlk1, followed by the 
processing of siPlk1 in transgenic ES clones, was confirmed by stem–
loop reverse transcription–PCR (RT–PCR; Supplementary Fig. S1e). 
The 75–80% Dox-induced reduction of Plk1 mRNA and the 80–90%  
protein reduction were determined (Supplementary Fig. S1f,g). The   
constitutive  expression  of  itetR  was  confirmed  (Supplementary   
Fig. S1g). Thus, on Dox-treatment of the ES cells, the shRNA cassette 
was integrated into the Rosa26 locus to allow inducible regulation 
of Plk1 expression or Plk1-inducible knockdown (iKD). In Plk1-
depleted ES cells the levels of other Plk members (Plk2-4) remained 
nearly unchanged supporting the specificity of our Plk1-targeted 
RNAi-approach (Supplementary Fig. S1h).
The generation and knockdown analysis of Plk1-iKD mice. Mice 
harbouring a heterozygous insertion of the shRNA (Plk1-iKD) were 
developed by tetraploid embryo complementation from the recom-
binant ES cells20. Analysis of the adult tissues before Dox-treatment 
confirmed  Plk1  expression  in  tissues  that  contained  an  elevated 
percentage of proliferating cells, including those of the testis, thy-
mus and spleen (Fig. 1a,b). Next, we verified the presence of the 
shRNA cassette in the tail clips of Plk1-iKD mice by PCR (Fig. 1c) 
and determined the efficiency of the shRNA cassette by monitor-
ing the activity of the cytomegalovirus-enhancer/β-actin (CAG)-
itetR system. The CAG-driven expression of itetR was detected in 
all  tested  tissues  (Fig.  1d).  The  subsequent  knockdown  analyses 
focused on adult tissues of wild-type (wt) mice that expressed Plk1 
at above background levels. Following 6 weeks of Dox-treatment, 
the quantitative reverse transcription (qRT–PCR) analysis revealed 
a substantial depletion of the Plk1 mRNA in various organs of Dox-
treated Plk1-iKD mice (testis: 86% reduction; bone marrow: 72%; 
and spleen: 60%) compared with the mRNA levels in Dox-treated 
wt mice (Fig. 1e). Analysis of the Plk1 protein expression confirmed 
efficient silencing in various murine organs (spleen, testis, ovary, 
stomach and colon) with residual levels ( < 10–20%; Fig. 1d). The 
expression of Plk3, which was previously shown to have overlap-
ping functions with Plk1 in a yeast complementation assay22,23, in 
the tissues of Dox-treated Plk1-iKD mice did not differ markedly 
compared with those in wt mice (Fig. 1d).
The generation and knockdown analysis of luciferase-iKD mice. 
A sequence against the firefly luciferase (Luc) gene served as a control 
siRNA that had no significant homology to any known murine genes, 
to establish a second iKD-mouse model to control the toxicity of 
siRNA expression under the Dox-inducible promoter. Luc-iKD mice 
were generated harbouring a CAG-itetR/H1tetO-shRNA/Luc-cassette   
inserted into the rosa26 locus according to the procedure described 
above.  We  could  not  detect  any  significant  changes  between  the   
Luc-iKD and control mice (both Dox-treated) in terms of the tran-
script levels of Plk1 (Fig. 1f) or other control genes (Cdk1, MAPK1, 
histone H1) in various tissues. This observation supports the notion 
that the Dox-inducible Pol III RNAi system used for our GEMM only 
marginally affects the expression of certain non-target genes.
Phenotypic analysis of Plk1-iKD mice. Plk1-iKD mice treated with 
Dox for 6 weeks underwent a thorough phenotypic analysis at the 
German  Mouse  Clinic  (GMC),  which  included  several  hundred 
parameters in dysmorphology, neurology, clinical chemistry, immu-
nology, allergy, steroid metabolism, cardiovascular function, noci-
ception, energy metabolism and pathology24. Selected parameters 
of the phenotypic analysis relevant to the function of Plk1 include 
the following: the complete morphological analysis did not reveal 
histological  differences  between  the  organs  of  Dox-treated  Plk1-
iKD mice and those of control animals (Supplementary Fig. S2a). 
Our GMC metabolic screening programme provided a compara-
tive analysis of bioenergetic parameters in the transgenic mice. The 
mechanisms that lead to disturbances in body weight regulation 
and energy metabolism were examined, including food consump-
tion, energy uptake, faeces production, energy content in the faeces 
and metabolized energy, which all remained unchanged. Despite 
their low values of assimilated energy, Dox-treated male Plk1-iKD ARTICLE     
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mice had a significantly increased body mass and rectal temperature 
compared with those of control animals (Supplementary Table S2). 
Given that the function of Plk1 is critical for mitosis, we examined 
the proliferative activity in iKD-mice: the proliferation index was 
moderately reduced in only the mucosal folds of the large intestines 
and in the ovarian follicles (Fig. 2a,b, Supplementary Tables S3 and 
S4). A significant induction of apoptosis as determined by the TdT-
mediated dUTP nick end labelling assay was not apparent in murine 
tissues. Considering that the Drosophila counterpart of Plk1, polo, is 
crucial for normal spermatogenesis in Drosophila25, we examined the 
testes of Plk1-iKD mice that exhibited a strong reduction (86%) in 
Plk1 levels. The weight of the testis from the Dox-treated Plk1-iKD 
mice was not significantly different from that of the control animals 
(0.095 versus 0.0985 g, P = 0.206), indicating normal spermatogen-
esis. Within the seminiferous epithelium, spermatogenesis proceeds 
from the basal to adluminal layers; thus, the mitotically active sper-
matogonia are located at the periphery of the epithelium (Fig. 2c). 
A morphometric analysis was performed on tubules that were in 
stages VII/VIII of the seminiferous epithelial cycle; these tubules 
exhibited the highest number of Ki-67-positive spermatogonia cor-
responding to the stage-specific pattern of murine spermatogonial 
mitotic activity26,27. The percentage of Ki-67-positive spermatogonia 
in control (87.3%) and Plk1-iKD mice (87.7%) was similar further 
suggesting that normal spermatogenesis occurred in both groups 
(Fig. 2c). Myelosuppression is a common side effect associated with 
the therapeutic use of anti-mitotic drugs such as taxanes5. To elu-
cidate whether the silencing of Plk1 causes similar adverse events,   
the GMC haematology and immunology screen focused on putative 
haematological changes. Neither the total white blood cell count nor 
the number of erythrocytes (red blood cells) or platelets was signifi-
cantly reduced in iKD mice. Although the proportions of B cells and 
NK cells (% of CD45 +  cells) were slightly increased, the granulocyte 
compartment was reduced in the Dox-treated iKD mice compared 
with those in the controls (Supplementary Table S5). The negative   
linear  correlation  between  the  frequencies  of  granulocytes  and   
B cells is a common observation in wt mice and reflects physiological 
regulation mechanisms28. As the proportion of granulocytes in the 
Dox-treated wt mice increased compared with that in the untreated 
controls and iKD mice, the Dox-treatment itself might have influ-
enced the proportions of leukocyte subsets in the peripheral blood. 
Because granulocyte proportions were still within the physiological 
range and the total white blood cell count was not reduced, we found 
no indication of neutropenia. Thus, after 6 weeks of Dox-treatment, 
we  observed  no  signs  of  bone  marrow  suppression  in  Plk1-iKD 
mice. Among the 21 parameters identified in the clinical–chemical 
plasma screen, substantial differences were detected only in serum 
ferritin, which has been implicated in the regulation of hematopoi-
esis29. Ferritin values were reduced in Plk1-iKD mice (male control: 
37.4 ± 3.1 ng ml − 1; female control: 37.9 ± 2.0 ng ml − 1; male transgenic: 
10.2 ± 1.4 ng ml − 1,  female  transgenic:  13.8 ± 1.0 ng ml − 1,  P < 0.001), 
suggesting an iron deficiency29 (Fig. 2d). However, the mice showed 
no signs of iron deficiency, anaemia, except that they had a slightly 
increased anisocytosis (red blood cell distribution width RDW) in 
the peripheral blood cell count. Overall, the examination indicated 
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Figure 1 | Analysis of RNAi-based depletion of Plk1 in the tissues of adult transgenic mice. (a) Poly(A) +  mRnA, isolated from the tissues of 
untreated adult mice and from 14-day-old embryos, was analysed by northern blot using 32P-labelled probes for Plk1 and β-actin, the loading control. 
Autoradiography was performed at 16 h. The bar graph represents the Plk1 mRnA expression standardized to the β-actin expression (means ± s.d., n = 5, 
for each tissue). (b) Total cellular protein prepared from the indicated tissues of untreated adult mice, embryos and nIH3T3 cells were separated by 
sDs–PAGE and immunoblotted for anti-Plk1, anti-β-actin, α-tubulin and GAPDH as loading controls (means ± s.d., n = 5, for each tissue). (c) PCR of mouse 
genomic DnA (tail clip) from wild-type (wt) mice, Plk1-iKD mice (kd) and template DnA as the positive control (pc) are presented. (d) Total cellular 
protein was prepared from the indicated tissues of Dox-treated adult Plk1-iKD and wt mice and separated by sDs–PAGE for anti-Plk1, -itetR, -Plk3 and 
-β-actin immunoblotting analyses. (e) Plk1 mRnA levels in the tissues of Dox-treated Plk1-iKD and wt mice relative to the Plk1 mRnA levels in the testis of 
untreated animals (100%), which was the tissue with the highest Plk1 mRnA expression, are shown (means ± s.d., n = 5, for each tissue). (f) Relative Plk1 
mRnA levels in the tissues of Dox-treated Luc-iKD (Luc-iKD  + Dox) animals are compared with the levels in untreated Luc-iKD animals (Luc-iKD -Dox; 
means ± s.d., n = 3, for each tissue).ARTICLE
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that during efficient Plk1 depletion ( > 80%) in the different organs, 
the low levels of any remaining Plk1 were sufficient to maintain cellu-
lar proliferation, spermatogenesis and hematopoiesis in adult mice.
The  long-term  Dox-treatment  ( > 30  months)  induced  only  a 
moderately  reduced  survival  rate  comparing  iKD  and  wt  mice   
(Supplementary Fig. S2b). To investigate the genomic stability of the 
Plk1-iKD-cassette, we performed a genotyping of a random collec-
tion of littermates. Considering that the first Plk1-iKD ES cells and 
mice were generated between June 2006 and August 2006, the pres-
ence of the iKD-cassette in mice of different ages in March 2011 
demonstrated the stability of the iKD for a period of 4.5–5 years 
(≥10 generations; Supplementary Fig. S2c). Moreover, the western 
blot analysis of splenocytes provided evidence for the long-term 
functionality of the iKD-cassette by showing stable itetR-expression 
and Dox-inducible depletion of Plk1 (Supplementary Fig. S2d).
Analysis of Plk1-depleted mammalian cells in culture. Next, to 
determine whether the Plk1-iKD mouse model recapitulates the 
cellular dependency of primary mammalian cells on Plk1, we exam-
ined the effects of gradual Plk1 depletion on the proliferation, cell-
cycle progression and apoptosis of mammalian cells under control-
led culture conditions. First, we tested the proliferative activity of 
different iKD mouse embryonic fibroblasts MEF clones (Fig. 3a). 
The Dox concentration (0–80 µg ml − 1) and the Plk1 protein levels 
were inversely correlated (Fig. 3a). Massive Plk1 depletion (90–95% 
reduction) with 80 µg ml − 1 Dox for 96 h had only a minor impact 
on the proliferative activity of different iKD MEF clones compared 
with the wt MEFs (MEF-wt: 12% reduction in proliferative activity, 
P = 0.04; MEF-kd12: 2% reduction, P = 0.71; MEF-kd17: 12% reduc-
tion,  P = 0.25;  and  MEF-kd18:  16%  reduction,  P = 0.24;  Fig.  3a). 
The gradual depletion of Plk1 in different MEF clones did not alter 
endogenous levels of Plk3 (Fig. 3a).
As a surrogate for the potential use of Plk1-specific drugs, we 
depleted Plk1 in human cells of different origins (human umbilical 
vein endothelial cells (HUVEC), fibroblasts and keratinocytes) by 
using our previously tested Plk1-specific siRNA30–33. First, we deter-
mined the transfection efficiency of the HUVEC using fluorescein-
labelled siRNAs by FACS analysis. Using a range of siRNA concentra-
tions (25–150 nM), we measured the uptake of labelled siRNA to be 
between 45 and 74% (Fig. 3b), which was followed by a pronounced 
reduction of Plk1 protein levels compared with a mismatch (MM) 
siRNA control (Fig. 3b). Despite efficient depletion of the Plk1 protein 
( > 90%), the growth properties of HUVEC did not vary significantly 
compared with siRNA MM-treated cells (HUVEC: 100 nM siRNA, 
reduction  6.2%  at  96 h,  P = 0.11,  Student’s  t-test;  Fig.  3b).  Silenc-
ing of Plk1 did not alter endogenous levels of Plk3 in HUVEC and 
fibroblasts (Fig. 3b,c). In addition, the depletion of Plk1 in human 
fibroblasts (≥90%) and keratinocytes ( > 95%) did not significantly 
inhibit their proliferative activity (fibroblasts: 100 nM siRNA, reduc-
tion 0.8% at 96 h, P = 0.89; keratinocytes: 100 nM siRNA, no reduc-
tion at 96 h, P = 0.11, Student’s t-test; Fig. 3c,d). In contrast, human 
Plk1-depeleted cancer cell lines of different organ origins (cervix, 
colon, breast, ovary and kidney) showed statistically significant dose-
dependent reductions in growth 96 h after transfection compared 
with that of the siRNA MM-transfected control cells (HeLa: 5 nM 
siRNA, 82% reduction, P < 0.001; SW480: 5 nM siRNA, 66%, P = 0.02; 
MDA-MB-231: 5 nM siRNA, 55%, P = 0.02; SK-OV-3: 5 nM siRNA, 
46%, P = 0.03; 293T: 5 nM siRNA, 51%, P = 0.007, Student’s t-test; 
Supplementary Fig. S3a–e). In summary, although the half-maximal 
depletion of the Plk1 protein (iKD50Plk1 − ) inhibited the growth of the 
tested cancer cells by 46–82%, the inhibitory effect in primary cells 
was  < 5% (Table 1), which mirrors previous observations in Plk1-
iKD mice and supports the model that low Plk1 levels can maintain 
nearly normal proliferative activity in primary mammalian cells.
Analysis of the mitotic progression of Plk1-depleted cells. Although 
siRNA MM-transfected cells (HeLa, SW480) regained 2n content 
after 15–18 h, the majority of Plk1-depleted cells did not complete 
their cell divisions (Supplementary Fig. S4a). The accumulation of 
phospho-histone  H3  (pHH3(S10))  and  the  anaphase-promoting 
complex/cyclosome  target  cyclin  B1  indicate  a  Plk1  depletion-
induced G2/M-arrest (Supplementary Fig. S4b). Dephosphorylation 
of  p-Cdk1(T14/Y15)  by  Plk1-activated  Cdc25C34  was  delayed  by 
several hours in the Plk1-depleted SW480 cells (Supplementary Fig. 
S4b). The accumulation of Emi1, Securin and pHH3(S10) provided 
further evidence for the mitotic arrest of Plk1-depleted SW480 cells 
(Supplementary Fig. S4b). The FACS analysis also revealed a pro-
nounced increase in the number of cells in the G2/M phase (HeLa: 
11→68%, 518% increase; and SW480: 24→48%, 100% increase; Sup-
plementary Fig. S4a). In contrast, at 24 and 48 h post transfection, the 
analysis of primary cells showed only a moderate increase in G2/M 
compared with siRNA MM-transfected cells (24 h: HUVEC 100 nM: 
27→33%, 22% increase; fibroblasts 100 nM 16→32%, 100% increase; 
and keratinocytes: 16→20%; 25% increase; Fig. 4a–c).
Considering the critical roles of polo and its homologues for the 
formation of an intact spindle apparatus in Drosophila and human 
cells35,36, we analysed the spindle structures of Plk1-depleted cells 
using anti-α-tubulin and -pericentrin mAbs for immunofluorescence   
staining. In a Plk1-depleted HeLa cell population, 31% of the cells 
displayed bipolar and 69% aberrant mitotic spindles (mostly monop-
olar spindles) associated with diffuse spindle pole morphology in 
the majority of cells (Supplementary Fig. S4c). In contrast, an equal 
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Figure 2 | Phenotypic comparison of Plk1-iKD and wt mice. (a–c) 
Representative examples are shown. (a) Determination of the proliferation 
index in the mucosal folds of the large intestine: Ki-67-stained cells in 
the crypts of the transverse mucosal folds of the large intestine of a wt 
and a Plk1-iKD mouse. sections are shown at two magnifications. upper 
scale bars, 500 µm, lower scale bars, 50 µm. (b) Determination of the 
proliferation index of the ovarian follicles: Ki-67-stained cells of an ovarian 
follicle of a wt and of a Plk1-iKD mouse. To calculate the proliferative index 
in the cyclic ovary, follicles of similar sizes were selected (red boxes). 
sections are shown at two magnifications. upper scale bars, 500 µm, 
lower scale bars 50 µm. (c) seminiferous tubules (stage VIII) in the 
testis of wt and iKD animals (primary magnification: ×20, arrows point 
to spermatogonia) were Bouin fixed, stained with hematoxylin/eosin or 
formalin fixed and stained for Ki-67 immunohistochemistry (brown nuclei 
of spermatogonia) with hematoxylin counterstaining. scale bar, 50 µm.  
(d) Ferritin values were determined using an Au400 autoanalyzer 
(olympus) in female and male Plk1-iKD mice and a sucrose-treated control 
group, which were all treated with Dox (means ± s.e.m., n = 3, for each 
sample). ***P < 0.001, student’s t-test, unpaired and two-tailed.ARTICLE     

nATuRE CommunICATIons | DoI: 10.1038/ncomms1395
nATuRE CommunICATIons | 2:395 | DoI: 10.1038/ncomms1395 | www.nature.com/naturecommunications
© 2011 Macmillan Publishers Limited. All rights reserved.
level of Plk1 depletion in keratinocytes induced aberrant mitotic 
spindles in only 14.2% of the cells associated with a mitotic index of 
7.5% compared with 0.47% in the siRNA MM-treated cells (Fig. 4d). 
Taken together, Plk1 silencing induced mitotic arrest accompanied 
by spindle defects in primary cells at a much lower frequency than 
those of different types of cancer cells.
Assessment of apoptosis following Plk1 silencing. To determine 
whether the mitotic delay is caused by chronic activation of the SAC 
resulting in cell death37–39, we analysed whether BubR1 was localized 
to  kinetochores,  because  unattached  kinetochores  are  associated 
with several checkpoint proteins, including BubR1. In a high per-
centage of kinetochores in mitotic Plk1-depleted HeLa cells, BubR1 
was enriched at the kinetochores (94.8%: 74/78), even in cells with 
a metaphase-like phenotype (Supplementary Fig. S4d). In contrast, 
in  Plk1-depleted  keratinocytes,  BubR1  was  frequently  found  on 
kinetochores in prometaphase, but not in metaphase (Fig. 4e). The 
ability of Plk1 RNAi keratinocytes to enter anaphase may therefore 
correlate with the lack of SAC activation.
Next, we evaluated the correlation between Plk1 silencing and 
death initiation. In a small collection of cancer cells, the death sen-
sitivity following Plk1 depletion varied considerably (Supplemen-
tary Fig. S5a–e). The RNAi-mediated iKD50Plk1 − -induced apoptosis 
in siRNA Plk1-treated cancer cells was between 1.1- and 7.6-fold 
higher compared with the apoptosis of the siRNA MM-treated cells 
(iKD50Plk1 −  HeLa: 2.0× relative (rel.) apoptosis; MDA-MB-231: 1.5×; 
SW480: 7.6×; and SK-OV-3: 1.1×; 293T: 2–3×; Supplementary Fig. 
S5a–e, Table 1). Remarkably, the viability of the primary cells was 
robust on Plk1 depletion; in ES cells, a crucial reservoir for hemat-
opoietic differentiation, the indications of apoptosis induction were 
weak (Fig. 5a). Despite a half-maximal depletion of the Plk1 protein, 
only relatively low levels of apoptosis were induced in the primary 
cells (iKD50Plk1 −  HUVEC: 1.3× rel. apoptosis; fibroblasts: 1.2×; and 
keratinocytes: 1.3×; Figs 5b–d, 3a, Table 1).
As p53-deficient cancer cells were more sensitive to Plk1 inhibi-
tion than cells with functional p53 (refs 40, 41), we evaluated the 
involvement of p53 status in apoptosis induced by Plk1 silencing in 
primary cells. Although the levels of Plk1 and p53 were efficiently 
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depleted in keratinocytes and HUVEC, apoptosis was not apparent, 
suggesting a different role of the p53 for the sensitivity of certain 
primary cells towards Plk1 inhibitors (Fig. 5e,f).
Assessing  the  effects  of  the  Plk1  inhibitor  BI  2536  in  MEFs. 
Remarkably, the treatment of MEFs with the small molecule inhibi-
tor BI 2536 (25–250 nM) revealed a pronounced growth inhibition 
at elevated concentrations (Fig. 6a), which was also reflected by the 
cell-cycle profile (Fig. 6b) at decreasing Plk1-specific kinase activi-
ties (Fig. 6c). The incubation with 50 nM BI 2536 induced aberrant 
mitotic spindles in 78% of MEFs associated with a mitotic index 
of  > 7.0% compared with control cells (Fig. 6d). As the EC50 values 
for BI 2536 in primary cells were reported to be 12–31 nM (ref. 42),   
we evaluated the induction of apoptosis in an extended range of con-
centrations (10 nM–2 µM; Fig. 6e,f). In contrast to the small extent 
of siRNA-induced apoptosis, BI 2536 treatment increased the level 
of apoptosis considerably in MEFs up to 20–30% annexin-positive 
cells at concentration ≥100 nM (Fig. 6e,f).
Evaluation of the tumour regression activity of Plk1-iKD. When 
transplanted into an ectopic location in athymic animals, ES cells 
can develop into tumours that are called teratocarcinomas43. Here, 
we compared Plk1- and Luc-iKD ES cells in vivo to determine the 
role of Plk1 during tumour development of primary cells. The Dox-
induced reduction of Plk1 mRNA and protein in Plk1- and Luc-
iKD ES cells was investigated (Fig. 7a). The injection of Plk1-iKD ES 
cells into the right flank and the Luc-iKD ES cells into the left flank 
of the same athymic mouse provided a side-by-side comparison in 
the presence or absence of Dox. Although the growth behaviour   
of the non-induced Plk1-, Luc-iKD ES cells and the Dox-induced 
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Figure 4 | Effect of Plk1 silencing on the cell-cycle distribution of primary mammalian cells. Primary cells (a) HuVEC and (b) fibroblasts and 
(c) keratinocytes were transfected with siRnA mm or siRnA Plk1 at different concentrations (50–100 nm) and analysed by FACs at 24 and 48 h. 
Representative histograms and the quantification of the cell-cycle analysis are shown. (d) Keratinocytes were labelled using Plk1, pericentrin and α-tubulin 
antibodies and 4,6-diamidino-2-phenylindole (DAPI) for the analysis by immunofluorescence microscopy. Representative examples of siRnA mm- and 
siRnA Plk1-transfected keratinocytes are depicted. The mitotic index and the percentage of cells with aberrant mitotic spindles were determined by 
counting 250–300 cells (means ± s.d., n = 5, for each sample of cells). scale bar, 5 µm. (e) Plk1-depleted keratinocytes were labelled using BubR1 and α-
tubulin antibodies and DAPI for the analysis by immunofluorescence microscopy. Representative examples of Plk1-transfected keratinocytes in different 
mitotic stages are depicted. scale bar, 5 µm.
Table 1 | The effect of Plk1 silencing on the proliferation and 
apoptosis of cancer cells and primary normal cells.
Cell type  iKD50Plk1– 
(nM siRNA Plk1) 
Growth 
inhibition96 h
Relative 
apoptosis24 h
(%) (fold)
Cancer cell lines
  293T 5–10 51 2–3
  sW480 5 66 7.6
  sK-oV-3  < 5 46 1.1
  mDA-mB-231 5 55 1.5
  HeLa 5 82 2.0
Normal cells
  HuVEC 60 5 1.3
  Fibroblasts 60  < 5 1.2
  Keratinocytes 20  ± no effect 1.3
The siRnA concentrations required for half-maximal depletion of the Plk1 protein (iKD50Plk1 − ) 
was correlated to the growth inhibition 96 h post transfection and apoptosis 24 h post 
transfection (n=3). Annexin V-based measurements of apoptosis were correlated with the 
dose-dependent knockdown of Plk1, which resulted in the apoptosis induced by iKD50Plk1 − .ARTICLE     
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Luc-iKD ES cells did not differ significantly, 38 days after inocula-
tion Dox-treated animals carrying Plk1-iKD ES cell-derived terato-
carcinomas exhibited a significant growth reduction of more than 
82% (P < 0.05, Student’s t-test) compared with the control (Fig. 7b,c).   
The subsequent protein analysis of tumour tissues ( ± Dox) con-
firmed the prominent depletion of Plk1 in Dox-induced Plk1-iKD 
ES cell-derived tumours (Fig. 7d). Our data strongly suggest that the 
inhibition of tumour growth derived from primary cells correlates 
to Plk1 depletion.
Discussion
Despite  their  proven  clinical  success  in  the  treatment  of  cancer 
patients, tubulin agents, such as taxanes or vinca alkaloids, affect nor-
mal cells and cause clinical symptoms including myelosuppression 
and  neuropathies5.  Thus,  to  minimize  these  side  effects,  non-
  structural components of mitosis have become the focus of poten-
tial drugs. Recent exploration of mitotic progression has identified 
critical effectors (kinesins, Aurora kinase, Plk1), all of which are 
drug-target classes5. The successful validation of Plk1 as a drug tar-
get based on its analysis in cancer cell lines in vitro and in vivo led 
to the rapid pharmaceutical development and clinical evaluation of 
a growing number of Plk inhibitors. Still, a major concern in target-
ing Plk1 for cancer therapy is the potential toxicity in normal tissues 
due to the pleiotropic functions of Plk1 in mitosis44. However, data 
on the role of Plk1 in primary and primary-like cells are rare and 
controversial: although the inhibition of Plk1 by antibody microin-
jection or with the small molecule inhibitor BI 2536 induced G2 or 
mitotic arrest, respectively, in both of these studies, the apoptotic 
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response was not determined36,42. A recent analysis describes a dif-
ferential effect of BI 2536 on the proliferative activity of primary 
cardiomyocytes and cardiac fibroblasts45. In contrast, Plk1 depletion 
in a nontransformed retinal epithelial cell line that stably expresses 
human telomerase reverse transcriptase (hTERT-RPE1) only had a 
minor effect on the kinetics and percentage of cells that enter and 
exit from mitosis41. Given that the immortalization of epithelial cells 
due to the expression of hTERT is accompanied by genetic and/or 
epigenetic alterations, the extent to which these cells reflect primary 
cells  is  unknown46.  Thus,  because  the  Plk1-knockout  mice  were 
not viable17, we decided to investigate the putative toxicities of Plk1 
silencing in a GEMM.
Although anti-mitotics such as Taxol or hypomorphic alleles of 
the Drosophila polo gene lead to disorders of spermatogenesis47,48, 
the testes, which exhibited the most pronounced iKD, lacked histo-
logical and functional abnormalities. In summary, our data suggest 
that an efficient, but not complete, knockdown of Plk1 in primary 
murine  cells  embedded  in  the  microenvironment  of  their  cor-
responding organs has only a minor physiological impact on the 
functions analysed like the proliferative activity. In our study, we 
extended our examination to primary cells in cell culture to deter-
mine whether the tissue context is critical for the dependence on 
Plk1 and whether the responses of primary cells to Plk1-depletion 
under controlled cell culture conditions are reflected in the Plk1-
iKD mice. The toxicity of Plk1 depletion suggested a model in which 
cancer cells of different origin, regardless of the transforming onco-
genic mechanism, are often addicted to Plk1. Notably, primary cells 
(even  those  removed  from  their  normal  microenvironment)  are 
largely resistant to apoptosis by low levels of Plk1, suggesting their 
weak dependence on Plk1 (non-addiction), which correlates with 
normal spindle dynamics and low SAC activities. Hence, our study 
suggests the existence of a therapeutic window for monospecific 
Plk1 inhibitors to kill tumour cells while sparing normal cells. This 
differential addiction of normal and cancer cells to Plk1 may also   
provide the rationale for using Plk1-monospecific drugs for chemo-
prevention  in  individuals  with  a  hereditary  cancer  background   
(for example, breast, colon and prostate) or in other patients with 
premalignant lesions such as ductal carcinoma in situ DCIS.
Clinical  trials  have  revealed  that  the  Plk1  inhibitor  BI  2536 
exhibits anti-tumour activity in patients, and reversible neutropenia 
was the main dose-limiting toxicity49,50. Plk1-iKD mice did not pro-
vide evidence for significant haematological alterations, although 
reduced ferritin levels indicate a depletion of iron stores that could 
induce hematopoietic abnormalities29. Obvious differential effects 
between  the  clinical  trials  and  our  iKD  model  could  be  due  to 
mechanistic differences of the siRNA and small molecule inhibitors. 
Whether the gradual depletion of Plk1 by RNAi allows primary cells 
with intact checkpoints to activate compensatory pathways involv-
ing related kinases remains to be explored. The expression of other 
representatives of the Plk family in Plk1-depleted cells and tissues 
opens the possibility of a substitutable role by other family mem-
bers. Notably, ATP-competitive inhibitors of Plk1, such as PHA-
680626 and BI 2536, scarcely discriminate between Plk1 and Plk3, 
because the residues that line the ATP-binding pocket are highly 
conserved within the Plk family except Plk4 (ref. 16). This simul-
taneous inhibition of different Plks including Plk1 might intensify 
the apoptotic response of primary cells as observed here in BI 2536-
treated MEFs.
Although more predictive models are urgently required in cancer 
drug development, GEMMs are not yet an integral part of pharma-
cological research. Inducible RNAi-based GEMMs provide a unique 
opportunity to reversibly control gene expression in different tissues 
of adult mice and to study responses to a target-specific KD. Our 
study represents an attempt to assess the feasibility of using induc-
ible RNAi-based GEMMs to predict the toxicities of targeted can-
cer drugs in mice. The similarities in KD responses observed in our 
Plk1-iKD mice and in our siRNA-treated primary cells validated the 
preclinical and predictive utility of iKD GEMMs in providing infor-
mation on potential mechanism-based toxicities that might arise as 
a result of the pharmacological inactivation of Plk1.
Methods
Isolation of total RNA from murine tissues. After Dox-treatment wt and 
Plk1-iKD mice were rapidly killed. Organs were prepared and stored in RNAlater 
Stabilization Reagent (Qiagen). For the RNA preparation, tissue pieces of 20 mg 
were dispersed with a PCR Tissue Homogenizing Kit (Omni International). Then 
total RNA was isolated using an RNeasy Mini Kit (Qiagen). The RNA was stored at 
concentrations of 50 ng µl − 1 to 1 µg µl − 1 at  − 20 °C.
Plk1 expression analysis. For northern blot experiments, 2 µg poly(A) +  RNA was 
subjected to 1.5% denaturating agarose gel-electrophoresis. The RNA was blotted 
to a Hybond-N +  nitrocellulose membrane (Amersham Biosciences) overnight by 
capillary forces. Subsequently, the membranes were heated at 80 °C (2 h) to fix the 
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Figure 6 | Assessment of cell-cycle properties and apoptosis in BI 
2536-treated MEFs. (a) Proliferative activity of mEFs at different BI 2536 
concentrations (25–250 nm; means ± s.d., n = 3, for each concentration). 
*P < 0.05, **P < 0.01, ***P < 0.001, student’s t-test, unpaired and two-
tailed. (b) FACs profile of exponentially growing mEFs treated for 24 h 
with BI 2536 (10 nm–2 µm). Percentage of cells in G2/m are given at each 
concentration. (c) Kinase activity of immunoprecipitated Plk1 protein from 
mEFs treated for 24 h with BI 2536 (10 nm–2 µm) using the cytoplasmic 
retention signal (CRs) of cyclin B1 as substrate. (d) mEFs were labelled 
using Plk1, pericentrin and α-tubulin antibodies and 4,6-diamidino-
2-phenylindole for the analysis by immunofluorescence microscopy. 
Representative examples of BI 2536-treated and control mEFs are 
depicted. scale bar, 5 µm. The mitotic index and the percentage of cells 
with aberrant mitotic spindles were determined by counting 250–300 
cells (means ± s.d., n = 5, for each sample of cells). (e) The correlation of 
BI 2536-mediated inhibition of the Plk1 and the induction of apoptosis 
in mEFs was analysed. The immunoblot for Plk1, β-actin and PARP is 
presented. (f) Annexin V-based measurements and caspase activity 
were determined in cell lysates of BI 2536-treated mEFs (24 h) using the 
Caspase-Glo 3/7 Assay (means ± s.d., n = 3, for each concentration).ARTICLE     
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RNA. The mRNA (Plk1, β-actin) was hybridized using a radioactive probe-con-
taining α-[P32]-dCTP (1×106 c.p.m. ml − 1). Probes for detecting the Plk1 mRNA 
were generated by standard PCR protocols using the sense primer 5′-TAATGACT 
CAACACGCCTGATT-3′ and the antisense primer 5′-AGCTCAGCAGCTTGTC 
TACCAT-3′. The β-actin-specific probe was generated using the sense primer 
5′-GAGGAGCACCCCGTGCTGCTGACCGAGGCC-3′ and the antisense primer 
5′-CCTGCTTGCTGATCCACATCTGCTGGAAGGTG-3′.
To quantify Plk1 transcripts, 1 µg of RNA was subjected to qRT-PCR (High 
Capacity cDNA Reverse Transcription Kit, Applied Biosystems). The qRT-PCR 
was conducted using a TaqMan Gene Expression Assay for murine Plk1 (Applied 
Biosystems). As an internal control in the TaqMan Assay, murine β-actin was used 
(Applied Biosystems).
Real-time PCR. This assay was performed using a standard TaqMan PCR Kit 
protocol in Applied Biosystems Step One. The 10 µl PCR reaction included 0.67 µl 
RT product, 1× TaqMan Universal PCR Master Mix, 0.2 µM TaqMan probe, 1.5 µM 
forward primer and 0.7 µM reverse primer. The reactions were incubated in a 384-
well plate at 95 °C (10 min), followed by 40 cycles of 95 °C (15 s) and 60 °C (1 min). 
All reactions were run in triplicate.
Preparation of primary cells and cell culture. MEFs were prepared from 15- 
day-old embryos by a standard procedure51. Splenocytes and bone marrow cells 
were isolated by standard protocols51,52. For Dox-treatment ES cells were cultured 
in DMEM (Invitrogen) containing 10% FCS from PAA, 4,500 mg l − 1 glucose, 1×  
non-essential amino acids and various concentrations of Dox (Sigma). The  
Dox-medium was prepared and changed each day.
For the isolation of HUVEC, an umbilical vein was cannulated with a sterile 
needle and perfused by PBS to remove remaining blood for subsequent incubation 
with α-chymotrypsin (Sigma). The umbilical cord was then flushed with RPMI 
1640 medium (Invitrogen). After centrifugation, cells were resuspended and cul-
tured in RPMI 1640 medium with 75 µg ml − 1 endothelial cell growth supplement 
(Sigma). Fibroblasts were cultured in DMEM with 10% FCS and keratinocytes 
in Dermalife K Medium Complete Kit (Cell Systems) at 37 °C and 5% CO2 in a 
humidified environment. Research studies involving the use of human specimens 
were reviewed and approved by the Institutional Review Board of the Goethe- 
University School of Medicine.
Cancer cell lines were purchased from the American Type Culture Collection 
and grown in the recommended medium supplemented with 10% FCS at 37 °C and 
5% CO2 in a humidified environment. SW480 (colon), MDA-MB-231 (breast) and 
293T (kidney/embryonic  + T) cells were grown in DMEM, HeLa (cervix) cells in 
MEM and SK-OV-3 (ovarian) cells in McCoy’s 5a. Media were obtained from Invit-
rogen and McCoy’s was from Biochrom.
Transfections. One day before transfection, 2×105 Art4.12 ES cells carrying the 
FRT/F3 configuration at rosa26 were plated on a 3-cm dish in 2 ml medium20. 
Before transfection 2 ml fresh medium was added. A volume of 3 µl FuGENE 6 
Reagent (Roche) were mixed with 100 µl serum-free medium (OptiMEM 1 with 
Glutamax-I, Invitrogen) and incubated (5 min). A volume of 100 µl of the FuGENE 
6/OptiMEM solution was added to 2-µg circular DNA (c = 0.33 µg µl − 1) and incu-
bated (15 min). Fresh medium was added to the transfected cells the following day. 
From day 2 on, the medium was changed daily, replaced by medium containing 
250 µg ml − 1 G418 (Geneticin, Invitrogen). The siRNA against Plk1 and the control 
siRNA MM31 were purchased from Sigma.
Normal cells were transfected with siRNA (10–150 nM) using Gene Silencer 
(BioCat). Cells were collected after 24 or 48 h. The transfection efficiency was 
ascertained by transfecting FITC-labelled siRNA (6 h) followed by FACS analysis 
(FACScan, BD Biosciences). Cancer cells were transfected with siRNAs (0.5–
10 nM) using the Oligofectamine protocol (Invitrogen). Control cells were treated 
as indicated for each experiment. Cells were collected 24 h after transfection for 
western blot, cell-cycle analysis and the apoptosis assay. For cell-cycle kinetics, the 
HeLa and SW480 cells were collected 0, 3, 6, 9, 12, 15 and 18 h after the addition of 
siRNAs. Proliferation was measured 0, 24, 48, 72 and 96 h after siRNA transfection.
Synchronization. Cells were incubated with 2 mM thymidine (Sigma; 16 h), 
washed extensively with PBS and released in fresh medium (8 h), followed by a 
second thymidine block (16 h)12.
Investigating the cell-cycle distribution by FACS analysis. Cells were seeded, 
transfected and collected after 24 and 48 h or every 3 h for the cell-cycle kinet-
ics. Cells were trypsinized, washed with PBS and fixed in 70% ice-cold ethanol 
(30 min). After centrifugation, the cells were resuspended in PBS and incubated 
with 300 µg ml − 1 RNAse A and 30 µg ml − 1 propidium iodide (30 min) at 37 °C. 
Finally, the cell-cycle quantification was performed by flow cytometry (FACScan, 
BD Biosciences) using ModFit (Verity Software House).
Immunofluorescence assays. Cells were grown on a glass coverslip, fixed and 
permeabilized with methanol ( − 20 °C), and washed with PBS before the addition 
of appropriate primary and secondary antibodies. Microscopy was performed  
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using a Zeiss Axio Imager.Z1 microscope (Zeiss) equipped with a ×40 objective, 
and the images were captured and processed using AxioVision Software (Zeiss).
Analysis of apoptosis. The Vybrant Apoptosis Assay Kit no. 2 (Alexa Fluor 488 
annexin V/propidium iodide staining, Invitrogen) was used, and the cells were 
analysed by flow cytometry using a FACScan (BD Biosciences)53. The activity of 
caspase-3/7 was determined using the Caspase-Glo 3/7 Assay according to the 
manufacturer’s instructions (Promega).
Antibodies. The following antibodies were used: mouse monoclonal antibodies 
against Plk1 (1:1,000), Cdk1 (1:1,000), cyclin B1 (1:5,000), p53 (1:2,000; Santa 
Cruz), Plk2 (1:500), β-actin (1:200,000; Sigma), Plk3 (1:1,000; BD Pharmingen), 
α-tubulin (1:500,000; Cedarlane/Biozol), Emi1 (1:500; Invitrogen, Karlsruhe),  
Securin (1:1,000; Abcam) and Ki-67 (1:100; DAKO), and rabbit polyclonal  
antibodies against PARP (1:1,000), Plk4 (1:1,000; Cell Signaling Technology/New 
England Biolabs), GAPDH (1:1,000; Abcam), Plk1 (1:1,000), pericentrin (1:500), 
caspase-3 (1:1,000), phospho-p53(Ser15) (1:500; Cell Signaling Technology/New 
England Biolabs), tet-Repressor (1:5,000; MoBiTec/Invitrogen), phospho-Histone 
H3(S10) (1:1,000; Millipore), and phospho-Cdk1 (T14/Y15) (1:1,000; Santa Cruz), 
which were obtained from commercial sources. HRP-conjugated secondary anti-
bodies (1:5,000) were from Santa Cruz; conjugated antibodies to FITC, CY3 and 
CY5 (1:1,000) were obtained from Jackson Immuno Research Labs; and  
biotinylated secondary antibodies were from DAKO.
Cell proliferation assay. Cell viability and proliferation assays were conducted 
using the CellTiter-Blue Cell Viability Assay (Promega). Cells were seeded in 
96-well plates and siRNA transfected or BI 2536 treated, and after 0, 24, 48, 72 
or 96 h, the fluorescence was measured using a Victor 1420 Multilabel Counter 
(Wallac/PerkinElmer).
Statistical methods. The mean mRNA levels measured by qRT-PCR were calcu-
lated using the averages of at least five independent samples. All other experiments 
were performed at least in triplicate. Mouse data depicted in Supplementary Table 
S2 and S5 were determined by two-way ANOVA, all other assays were analysed by 
Student’s t-test, unpaired and two-tailed. Significant differences are indicated with 
stars (*P < 0.05, **P < 0.01, ***P < 0.001).
Tumour mouse model. Each flank of 8-week-old female athymic mice (Harlan-
Winkelmann) was inoculated subcutaneously with 2×106 ES cells resuspended in 
0.25 ml sterile saline solution. Luc-iKD ES cells were inoculated on the left flank, 
whereas Plk1-iKD ES cells were inoculated on the right flank. Mice were distrib-
uted randomly into two groups (12 animals each) for the subsequent analysis of 
tumour development with and without Dox-treatment. Dox (Sigma) was applied as 
0.2% solution in the drinking water with additional 3% sucrose dissolved in natural 
mineral water starting 2 days after inoculation. Drinking water for control mice 
contained 3% sucrose without Dox. Tumours (teratocarcinomas) were measured 
in two right-angled dimensions by a sliding caliper three times a week. Absolute 
tumour volumes were evaluated according to V (mm3) = π/6 ab2 with a > b. After 
inoculation measurements started at day 7 and finished at day 38 followed immedi-
ately by killing the animals. Three individual tumours from all four groups  
(Luc-iKD- and Plk1-iKD-ES cells,  ± Dox) were analysed. The use of animals  
complied with the regulations of the Goethe-University.
Additional methods. Specific reagents and methodology for the inducible shRNA 
expression vector (exchange vector), generation of ES cells, mice, analysis of mouse 
genotypes, stem–loop RT-PCR, western blot, pathology screen, immunohisto-
chemistry, collection and analysis of blood samples are all described in the  
Supplementary Methods. 
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